- Home
- DSM vs ATAI Comparison
DSM vs ATAI Comparison
Compare DSM & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- ATAI
- Stock Information
- Founded
- DSM 1989
- ATAI 2018
- Country
- DSM United States
- ATAI Germany
- Employees
- DSM N/A
- ATAI N/A
- Industry
- DSM Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- ATAI Health Care
- Exchange
- DSM Nasdaq
- ATAI Nasdaq
- Market Cap
- DSM 270.9M
- ATAI 282.6M
- IPO Year
- DSM N/A
- ATAI 2021
- Fundamental
- Price
- DSM $5.75
- ATAI $1.39
- Analyst Decision
- DSM
- ATAI Strong Buy
- Analyst Count
- DSM 0
- ATAI 3
- Target Price
- DSM N/A
- ATAI $10.50
- AVG Volume (30 Days)
- DSM 161.7K
- ATAI 1.3M
- Earning Date
- DSM 01-01-0001
- ATAI 05-19-2025
- Dividend Yield
- DSM 3.97%
- ATAI N/A
- EPS Growth
- DSM N/A
- ATAI N/A
- EPS
- DSM N/A
- ATAI N/A
- Revenue
- DSM N/A
- ATAI $308,000.00
- Revenue This Year
- DSM N/A
- ATAI $65.58
- Revenue Next Year
- DSM N/A
- ATAI N/A
- P/E Ratio
- DSM N/A
- ATAI N/A
- Revenue Growth
- DSM N/A
- ATAI N/A
- 52 Week Low
- DSM $4.69
- ATAI $1.03
- 52 Week High
- DSM $6.05
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- DSM 60.00
- ATAI 46.46
- Support Level
- DSM $5.63
- ATAI $1.29
- Resistance Level
- DSM $5.74
- ATAI $1.54
- Average True Range (ATR)
- DSM 0.07
- ATAI 0.09
- MACD
- DSM 0.04
- ATAI -0.00
- Stochastic Oscillator
- DSM 94.74
- ATAI 37.04
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.